Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Mario Luca Morieri, Angelo Avogaro & Gian Paolo Fadini. (2020) Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice. Diabetes, Metabolic Syndrome and Obesity 13, pages 4221-4234.
Read now
Read now
Articles from other publishers (15)
Annabel Barrett, Nele Debackere, Anderson Ribeiro, Karabo Keapoletswe, Rebecca Zingel & Briana Coles. (2023) Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes in the United Kingdom and Germany: A Retrospective Cohort Study. Advances in Therapy 40:8, pages 3446-3464.
Crossref
Crossref
Heike Jung, Sascha R. Tittel, Nanette C. Schloot, Elke Heitmann, Thorsten Otto, Jeremie Lebrec, Marianne Pavel & Stefanie Lanzinger. (2023) Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon‐like peptide‐1 receptor agonist: A retrospective analysis of the Diabetes Prospective Follow‐Up Registry. Diabetes, Obesity and Metabolism 25:7, pages 1813-1822.
Crossref
Crossref
Lai San Tham, Kevin M. Pantalone, Kathleen Dungan, Kashif Munir, Cheng Cai Tang, Manige Konig & Anita Y. M. Kwan. (2021) A model‐based simulation of glycaemic control and body weight when switching from semaglutide to 3.0‐ and 4.5‐mg doses of once‐weekly dulaglutide. Diabetes, Obesity and Metabolism 24:2, pages 302-311.
Crossref
Crossref
Luis-Emilio García-Pérez, Kristina S. Boye, Myriam Rosilio, Heike Jung, Elke Heitmann, Kirsi Norrbacka, Marco Orsini Federici, Raffaella Gentilella, Bruno Guerci, Francesco Giorgino, Ulrich Aigner & Hélène Sapin. (2021) The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics. Diabetes Therapy 12:7, pages 1929-1946.
Crossref
Crossref
Juris J. Meier. (2021) Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation. Frontiers in Endocrinology 12.
Crossref
Crossref
Sarah Zimner Rapuch, Victoria Divino, Kirsi Norrbacka, Kristina Boye, Jeremie Lebrec, Myriam Rosilio, Mitch DeKoven & Bruno Guerci. (2021) Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis. Diabetes Therapy 12:5, pages 1553-1567.
Crossref
Crossref
Kirsi Norrbacka, Antoni Sicras-Mainar, Jeremie Lebrec, Esther Artime, Silvia Díaz, Santiago Tofé-Povedano, Ignacio Hernández & Irene Romera. (2021) Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain. Diabetes Therapy 12:5, pages 1535-1551.
Crossref
Crossref
Daria Ja’arah, Mazhar Salim Al Zoubi, Gamal Abdelhady, Firas Rabi & Murtaza M Tambuwala. (2021) Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia. Clinical Medicine Insights: Endocrinology and Diabetes 14, pages 117955142110516.
Crossref
Crossref
Chun-Ting Yang, Chen-Yi Yang, Huang-Tz Ou & Shihchen Kuo. (2020) Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study. Cardiovascular Diabetology 19:1.
Crossref
Crossref
Jaime P. Almandoz, Ildiko Lingvay, Javier Morales & Carlos Campos. (2020) Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance. Clinical Diabetes 38:4, pages 390-402.
Crossref
Crossref
Susan Robinson, Kristina S. Boye, Reema Mody, Alena Antonie Strizek, Manige Konig, Raleigh E. Malik & Tessa Kennedy-Martin. (2020) Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature Review. Diabetes Therapy 11:7, pages 1437-1466.
Crossref
Crossref
Mario Luca Morieri, Mauro Rigato, Vera Frison, Natalino Simioni, Michele D'Ambrosio, Federica Tadiotto, Agostino Paccagnella, Annunziata Lapolla, Angelo Avogaro & Gian Paolo Fadini. (2020) Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies. Metabolism 106, pages 154190.
Crossref
Crossref
Lesley J. Scott. (2020) Dulaglutide: A Review in Type 2 Diabetes. Drugs 80:2, pages 197-208.
Crossref
Crossref
Victoria Divino, Kristina S. Boye, Jeremie Lebrec, Mitch DeKoven & Kirsi Norrbacka. (2019) GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data. Diabetes Therapy 10:3, pages 1067-1088.
Crossref
Crossref
Gian Paolo Fadini, Bendetta Maria Bonora, Annunziata Lapolla, Bruno Fattor, Paola Silvia Morpurgo, Natalino Simioni & Angelo Avogaro. (2019) Comparative effectiveness of exenatide once‐weekly versus liraglutide in routine clinical practice: A retrospective multicentre study and meta‐analysis of observational studies. Diabetes, Obesity and Metabolism 21:5, pages 1255-1260.
Crossref
Crossref